The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion
Status:
Completed
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
Glucagon like peptide 1 is produced in enteroendocrine L cells in the small intestine
stimulated by peroral food intake. GLP-1 induces insulin secretion, and analogues are used in
the treatment of DM2 (type 2 diabetes mellitus). Recently it was found, that levels of GLP-1
are increased in response to acipimox. The hypothesis is that G protein coupled receptors on
enteroendocrine L cells bind acipimox and thereby induce GLP-1 secretion.
In a controlled, open, randomized experiment, eight healthy, overweight men will be studied
on an intervention day, where they receive acipimox, and on a control day. The study day
includes an OGTT (oral glucose tolerance test), blood samples before and after the OGTT and a
biopsy from adipose tissue.